Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 10.71%.

  • Heron Therapeutics' EBIT Margin rose 28800.0% to 10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 198500.0%. This contributed to the annual value of 7.99% for FY2024, which is 790800.0% up from last year.
  • Heron Therapeutics' EBIT Margin amounted to 10.71% in Q3 2025, which was up 28800.0% from 4.4% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EBIT Margin ranged from a high of 10.23% in Q4 2024 and a low of 269.43% during Q2 2021
  • Its 5-year average for EBIT Margin is 109.52%, with a median of 79.31% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -527200bps in 2021, then soared by 1914100bps in 2022.
  • Over the past 5 years, Heron Therapeutics' EBIT Margin (Quarter) stood at 259.2% in 2021, then soared by 74bps to 67.79% in 2022, then skyrocketed by 56bps to 29.85% in 2023, then soared by 134bps to 10.23% in 2024, then plummeted by -205bps to 10.71% in 2025.
  • Its EBIT Margin was 10.71% in Q3 2025, compared to 4.4% in Q2 2025 and 8.11% in Q1 2025.